Signed Agreement With Anheart Therapeutics To Obtain Exclusive Sales Rights For Anheart's Taletrectinib In Japan Market
Oct 30 (Reuters) - Nippon Kayaku Co Ltd 4272.T :
* NIPPON KAYAKU CO LTD: SIGNED AGREEMENT WITH ANHEART
THERAPEUTICS
TO OBTAIN EXCLUSIVE SALES RIGHTS FOR ANHEART'S TALETRECTINIB IN
JAPAN MARKET
Source text for Eikon: ID:nTSvd8bdc4
Further company coverage: 4272.T
(Reporting by Tokyo Newsroom)
((+81345201189;))
Recent news on Nippon Kayaku Co
See all newsBrief: Silchester Cuts Stake In Nippon Kayaku To 4.68% From 5.76%, Filing Shows
Brief: Silchester Cuts Stake In Nippon Kayaku Co To 4.68% From 5.76%, Filing Shows
To Buy Up To 13,000,000 Own Shares, 8.75% Of Outstanding Shares
Table: Nippon Kayaku -2025/26 group results
Table: Nippon Kayaku -2025/26 parent results